Ultromics key facts
as of Oct 2026- Developer of an artificial intelligence-based cardiovascular diagnostic technology designed to detect heart failure and amyloidosis.
- Ultromics is valued at approximately $131.0M as of Oct 2026 (last reported valuation).
- It has raised $135.8M; the latest was Later Stage VC ($64.6M) in Jul 2025.
- Notable investors include GV, Tech Nation Group, Future Planet Capital, University of Oxford, Lightrock — 27 tracked in total.
- Status: Privately Held (backing).
Ultromics's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 27 names
- ·Watch Ultromics: the Monday email on marks, rounds and moves
Ultromics funding rounds
No funding rounds for Ultromics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ultromics
27+Ultromics valuation
Ultromics's last reported valuation was $131 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Ultromics investors
27 investors are on record for Ultromics, including GV, Tech Nation Group, Future Planet Capital and University of Oxford. By type, the record holds 6 venture capital firms and 1 hedge fund.
About Ultromics
Developer of an artificial intelligence-based cardiovascular diagnostic technology designed to detect heart failure and amyloidosis. The company offers machine learning models applied to electrocardiogram data to extract clinically relevant patterns, enabling clinicians to improve diagnostic accuracy and make informed decisions from complex cardiac signals.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2017
- Employees
- 78
- Website
- ultromics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.